In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t- butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886)

Molecular Pharmacology

Volumn 73, Issue 5, 2008, Pages 1434-1443

  Biserni, Andrea ^a,b   Giannessi, Fabio ^c   Sciarroni, Anna Floriana ^c   Milazzo, Ferdinando Maria ^c   Maggi, Adriana ^a   Ciana, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Transgenic Operative Products srl   (Italy)

^c Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; LUCIFERIN; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; ROSIGLITAZONE; ST 1929; ST 2518; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; LIGAND; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION; IMAGING SYSTEM; IN VIVO STUDY; LUNG; MALE; MONOTHERAPY; MORNING DOSAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SIGNAL TRANSDUCTION; TESTIS; ANIMAL; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; TIME; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; WHOLE BODY IMAGING;

ANIMALS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GENES, REPORTER; INDOLES; LIGANDS; LUCIFERASES; LUNG; MALE; MICE; MICE, TRANSGENIC; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA; PYRIMIDINES; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TESTIS; TIME FACTORS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 42449128827     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.042689     Document Type: Article

References (48)

1. Albet S, Causeret C, Bentejac M, Mandel JL, Aubourg P, and Maurice B (1997) Fenofibrate differently alters expression of genes encoding ATP-binding transporter proteins of the peroxisomal membrane. FEBS Lett 405:394-397.
2. Anghel SI and Wahli W (2007) Fat poetry: a kingdom for PPARgamma. Cell Res 17:486-511.
3. Berger J and Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435.
4. Berger JP, Akiyama TE, and Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244-251.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiveron C, and Maggi A (2001) Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol 15:1104-1113.
7. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C, and Maggi A (2003) In vivo imaging of transcriptionally active estrogen receptors. Nat Med 9:82-86.
8. Ciana P, Biserni A, Tatangelo L, Tiveron C, Sciarroni AF, Ottobrini L, and Maggi A (2007) A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Mol Endocrinol 21:388-400.
9. Conner P (2007) Breast response to menopausal hormone therapy-aspects on proliferation, apoptosis and mammographic density. Ann Med 39:28-41.
10. Dell'Uomo N, Tassoni E, Brunetti T, Pessotto P, Sciarroni AF, Milazzo FM, De Angelis F, Peschechera A, Tinti MO, Carminati P, et al. (2006) 2-{3-[2-(4-chlorophenyl)ethoxy]phenylthio}-2-methylpropanoic acid: a fibrate-like compound with hypolipidemic and antidiabetic activity. Chem Med Chem 1:49-53.
11. Evans RM, Barish GD, and Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10:355-361.
12. Fruchart JC, Duriez P, and Staels B (1999) Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245-257.
13. Gale EA (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870-1875.
14. Graham DJ, Green L, Senior JR, and Nourjah P (2003) Troglitazone-induced liver failure: a case study. Am J Med 114:299-306.
15. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, and McMurray JJ (2007) Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357:28-38.
16. Jordan VC (2001) Selective estrogen receptor modulation: a personal perspective. Cancer Res 61:5683-5687.
17. Katzenellenbogen JA, O'Malley BW, and Katzenellenbogen BS (1996) Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 10:119-131.
18. Kehrer JP, Biswal SS, La E, Thuillier P, Datta K, Fischer SM, and Vanden Heuvel JP (2001) Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J 356:899-906.
19. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774.
20. Kostadinova R, Wahli W, and Michalik L (2005) PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 12:2995-3009.
21. Kota BP, Huang TH, and Roufogalis BD (2005) An overview on biological mechanisms of PPARs. Pharmacol Res 51:85-94.
22. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, and Lecka-Czernik B (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-2680.
23. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650.
24. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
25. Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT, and van der Burg B (2004) Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol 32:689-701.
26. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCt) method. Methods 25:402-408.
27. Ma ZQ, Spreafico E, Pollio G, Santagati S, Conti E, Cattaneo E, and Maggi A (1993) Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci U S A 90:3740-3744.
28. Maggi A, Ottobrini L, Biserni A, Lucignani G, and Ciana P (2004) Techniques: reporter mice - a new way to look at drug action. Trends Pharmacol Sci 25:337-342.
29. Masubuchi Y (2006) Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21:347-356.
30. McKenna NJ, Lanz RB, and O'Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344.
31. Montani C, Penza M, Jeremic M, Biasiotto G, La Sala G, De Felici M, Ciana P, Maggi A, and Di Lorenzo D (2008) Genistein is an efficient estrogen in the whole body throughout mouse development. Toxicol Sci 67:681-694.
32. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
33. O'Malley BW (2007) Coregulators: from whence came these "master genes". Mol Endocrinol 21:1009-1013.
34. Patrone C, Gianazza E, Santagati S, Agrati P, and Maggi A (1998) Divergent pathways regulate ligand-independent activation of ER alpha in SK-N-BE neuroblastoma and COS-1 renal carcinoma cells. Mol Endocrinol 12:835-841.
35. Psaty BM and Furberg CD (2007) The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357:67-69.
36. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, Ruiz M, Pampols T, Giros M, and Mandel JL (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 13:2997-3006.
37. Rampler H, Weinhofer I, Netik A, Forss-Petter S, Brown PJ, Oplinger JA, Bugaut M, and Berger J (2003) Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy. Mol Genet Metab 80:398-407.
38. Reeves GK, Beral V, Green J, Gathani T, and Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7:910-918.
39. Robyr D, Wolffe AP, and Wahli W (2000) Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 14:329-347.
40. Rosen ED, Walkey CJ, Puigserver P, and Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14:1293-1307.
41. Rzonca SO, Suva LJ, Gaddy D, Montague DC, and Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406.
42. Shi GQ, Dropinski JF, McKeever BM, Xu S, Becker JW, Berger JP, MacNaul KL, Elbrecht A, Zhou G, Doebber TW, et al. (2005) Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. J Med Chem 48:4457-4468.
43. Stauber AJ, Brown-Borg H, Liu J, Waalkes MP, Laughter A, Staben RA, Coley LC, Swanson C, Voss KA, Kopchick JJ, et al. (2005) Constitutive expression of peroxisome proliferator-activated receptor α-regulated genes in dwarf mice. Mol Pharmacol 67:681-694.
44. Swaby RF, Sharma CG, and Jordan VC (2007) SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 8:229-239.
45. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, and Green S (1992) The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11:433-439.
46. Watkins PB and Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917.
47. Woolf AD (2007) An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 19:370-375.
48. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, and Greene GL (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18:413-424.